Natalizumab

AttackMS: assessing the feasibility of multiple sclerosis treatment within 14 days of presentation 6:02
AttackMS: assessing the feasibility of multiple sclerosis treatment within 14 days of presentation
Klaus Schmierer • 1 Jul 2022
Updates on natalizumab and anti-CD20 antibodies for MS 2:21
Updates on natalizumab and anti-CD20 antibodies for MS
Massimo Filippi • 26 Jun 2022
Natalizumab concentrations during pregnancy in MS patients 1:16
Natalizumab concentrations during pregnancy in MS patients
Alyssa Toorop • 26 Jun 2022
The protective effect of pregnancy in MS 1:18
The protective effect of pregnancy in MS
Kristen Krysko • 4 Apr 2022
Managing MS relapses during pregnancy 2:25
Managing MS relapses during pregnancy
Kristen Krysko • 4 Apr 2022
Benefits of personalized extended interval dosing of natalizumab 0:56
Benefits of personalized extended interval dosing of natalizumab
Alyssa Toorop • 26 Jun 2022
NEXT-MS: personalized extended interval dosing of natalizumab in RRMS 2:18
NEXT-MS: personalized extended interval dosing of natalizumab in RRMS
Alyssa Toorop • 26 Jun 2022
Novel agents to control seizures & target epileptogenesis 1:28
Novel agents to control seizures & target epileptogenesis
Claude Steriade • 24 Mar 2022
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs 3:15
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs
Virginia Meca-Lallana • 28 Feb 2022
Autoreactive T-cell responses in multiple sclerosis: unanswered questions 2:14
Autoreactive T-cell responses in multiple sclerosis: unanswered questions
Olivia Thomas • 21 Oct 2021
Characterizing the autoantigen-specific T-cell repertoire in MS 6:29
Characterizing the autoantigen-specific T-cell repertoire in MS
Olivia Thomas • 21 Oct 2021
Comparing exit strategies in natalizumab-responders at high risk for PML 7:33
Comparing exit strategies in natalizumab-responders at high risk for PML
Emanuele D'Amico • 30 Sep 2021
Discovering markers of disease progression in patients with MS treated with natalizumab 2:08
Discovering markers of disease progression in patients with MS treated with natalizumab
Charlotte Teunissen • 6 Oct 2021
COVID-19 cases in MS patients receiving IV therapy 1:49
COVID-19 cases in MS patients receiving IV therapy
Celia Oreja-Guevara • 14 Oct 2021
Humoral response to COVID-19 vaccination in patients with MS 6:28
Humoral response to COVID-19 vaccination in patients with MS
Celia Oreja-Guevara • 14 Oct 2021
Long-term efficacy outcomes of natalizumab vs. fingolimod in highly active RRMS 3:30
Long-term efficacy outcomes of natalizumab vs. fingolimod in highly active RRMS
Nikolaos Grigoriadis • 20 Sep 2021
The content of VJNeurology is intended for healthcare professionals